Calls for papers
-
Australian device company Medical Developments International (MVP) has acquired Australian spacer company Breath-A-Tech from Avita Medical for A$2.47 million, comprised of A$2.029 million cash up front and 117,894 shares of MVP stock, which will be… Read more . . .
-
The Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) has acquired Takeda’s Surfactant and Continuous Powder Aerosolization (CPA) program, the company said. According to the announcement, the transfer took place as Takeda shut down its… Read more . . .
-
CDMO Cirrus Pharmaceuticals, a subsidiary of Kemwell, has announced the availability of cGMP inhaler manufacturing services for early phase clinical trials materials at its new facility in Raleigh-Durham, NC. Cirrus announced in October 2014 that… Read more . . .
-
Johnson & Johnson subsidiary McNeil Consumer Healthcare says that Rhinocort budesonide nasal spray is now available over the counter in the US for the treatment of allergic rhinitis. McNeil acquired the OTC rights to AstraZeneca’s… Read more . . .
-
Egalet Corporation has announced that it has partnered with Septodont, Inc. to promote Sprix ketorolac tromethamine nasal spray to US dentists. Septodont will pay Egalet an undisclosed licensing fee up front, sales-based milestones and a… Read more . . .
-
MannKind Corporation held an investor call on February 3, 2016 in which CEO Matt Pfeffer said that the company might co-promote Afrezza inhaled insulin with a partner or partners after Sanofi returns the rights, but… Read more . . .
-
Spiriva Respimat is now available in US pharmacies for the treatment of asthma, Boehringer Ingelheim has announced. The FDA approved Spiriva Respimat for the treatment of asthma in patients aged 12 and older in September… Read more . . .
-
Discovery Laboratories, which recently released positive Phase 2a data for its Aerosurf aerosolized KL4 surfactant and advanced the product into Phase 2b, has announced the appointment of Craig Fraser as President and CEO. Fraser was… Read more . . .
-
OptiNose has been selected by the Research Council of Norway for a grant of up to NOK 15.9 million ($1.8 million) to study intranasal delivery of Orexin-A for the treatment of narcolepsy. The grant is… Read more . . .
-
Pulmatrix has announced that a pilot bioequivalence study of 5 formulations of its PUR0200 DPI for the treatment of COPD has begun enrollment. The company is partnered with Mylan on development of the DPI. According… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland